Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. OCREVUS
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

OCREVUS

Medicine - Posted on Jun 12 2025
Active substance (DCI)
  • ocrelizumab
history (4)
  • 5/14/25

    OCREVUS (ocrelizumab) - Sclérose en plaques

    Réévaluation à la demande de la CT. L'essentiel Avis favorable au maintien du remboursement dans le traitement des patients ...
    CAV :
    54321
    icône flèche
  • 5/14/25

    OCREVUS (ocrelizumab) - Sclérose en plaques

    Primo-inscription L'essentiel Avis favorable au remboursement dans : le traitement des patients adultes atteints de sclérose...
    CAV :
    54321
    icône flèche
  • Economic analysis
    7/11/18

    OCREVUS (ocrelizumab), immunosuppressant

    Moderate clinical benefit in early-stage primary progressive multiple sclerosis (PP-MS) in terms of disease duration and deg...
    CAV :
    54321
    icône flèche
  • Economic analysis
    5/30/18

    OCREVUS (SEP récurrente)

    OCREVUS (SEP récurrente)
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L04AG08
Manufacturer
ROCHE SAS
Presentation

OCREVUS 300 mg, solution à diluer pour perfusion
1 flacon en verre de 10 mL (CIP : 34009 550 483 6 7)

OCREVUS 920 mg, solution injectable
1 flacon en verre de 23 mL (CIP : 34009 551 018 9 5)

All our publications
    Autoimmune diseases Central nervous system diseases Demyelinating diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mFFv2jAQx9/5FFHeSQiMtkyBamPthtSqjBZt2ktlkqOYpXZ6toHu088hVAuTo7YGP8Z2/nfx/f3zKfH55jHzVoCCctb3o6Dle8ASnlL20Pend5fNM/980IiXZEUqy06DVhC1fS/JiBB9v5gNZkCYCH5eX30B/T6gP2h4MZ8tIZF765SkWfCNiMU1yYs1XrziNPUeQS542vdzJbejXiwk6iwGa46/RU4SiMPdSHV2ef+hOh6HhdgbVJUAvCLswSgKzEozUYjA5JBIeOD4XJNvx0qbigkIrjCBMZGLMfIVTSE1hpiTTIBVkPk6vQVcZSCLIEbxcJk8CitxsiSbCTyNzEl/0rNDuZHNVjM67bZbZ71e96TXiaxCYWWrzFXQHxHmOab37d5ZJ+qchMBCniCslLAsz5ijJJmjwlAx3PeWozgIT68aIKUiz8hzsBS57VYRJHoaUBPA3YcUX3CHmkmZ3rP/9JnKsvCdWU93xHCUcQGkIVdM1oDjcmK7EUPOJGzqK2rHOrnZeZGCOJ7sH87MnB+rWUYTW6pp7igQcjoZ1UPtyDz4TARM0R0QflCW8rU4PmiqhXWUfb5lpVFU1yAqinASdbvW5+iXdlHNPXOhkOcQagRRcQhZRmzOD2WKNqZZ6sWWx3TktuHhCcmgpuVpWhJGW/GlQ3NmdncHqZwwin69uLN1yHcF+Hy7fTRK07Rfra0dgV1gXVuyNvf3G7w85076YYVmfiykzMXHMFwQ0RRE71AwRxd4r1yq7ppxJzd32cmUiHSU+qy8+95eINtz9tq9fmivunt/1xMbY0hUcEAdSiQ7A+fo4vgs/teoOkt7vAcOd2G2TSWRlDNXnY6amducQ+mvS8suUfPhZj6nNf9Gaq0Zh+V/mUEjDot/MoPGXyBh6f8=
v4pEruLNWTeezVnw